[Market Focus] Rokit Healthcare Surges 23% on News of U.S. Entry for AI Kidney Disease Prediction Solution

Rokit Healthcare is showing a strong increase of around 23% following news of its entry into the U.S. market with its proprietary artificial intelligence (AI) kidney disease prediction solution.

As of 9:23 a.m. on March 18, Rokit Healthcare was trading at 1,226,000 won, up 23.84% (236,000 won) from the previous trading day.

The previous day, Rokit Healthcare announced that it had completed U.S. market certification for its AI kidney disease prediction solution, "AI Kidney," and had signed a license-out agreement for commercialization.

Set to officially launch in the U.S. next month, this solution enables testing with just a single drop of blood and, through AI algorithms, provides more accurate predictions of kidney function and estimated glomerular filtration rate trends over the next five years.

The key aspect of this contract is the royalty rate of approximately 18%. Given that royalties for most bio and medical device license agreements are typically set in the single-digit percentage range, this is considered a high royalty rate.

With a diagnostic royalty of about 50,000 won per user, Rokit Healthcare has set a goal of securing a 5% share among approximately 35.5 million chronic kidney disease patients in the United States.

This content was produced with the assistance of AI translation services.